List of Rhofade drug patents
Rhofade is owned by Epi Hlth.
Rhofade contains Oxymetazoline Hydrochloride.
Rhofade has a total of 8 drug patents out of which 0 drug patents have expired.
Rhofade was authorised for market use on 18 January, 2017.
Rhofade is available in cream;topical dosage forms.
Rhofade can be used as once daily topical treatment of persistent facial erythema associated with rosacea in female adults, once daily topical treatment of persistent facial erythema associated with rosacea in adults, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment.
The generics of Rhofade are possible to be released after 11 June, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815929 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(11 months from now) | |
| US8420688 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(1 year, 5 months from now) | |
| US7812049 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(5 years from now) | |
| US8883838 | EPI HLTH | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(8 years from now) | |
| US9974773 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
| US10751325 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
| US10335391 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
| US11517560 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in female adults
Dosage: CREAM;TOPICAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic